Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T47165
(Former ID: TTDI02005)
|
|||||
| Target Name |
Neural cell adhesion molecule (NCAM)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| 2 | Alzheimer disease [ICD-11: 8A20] | |||||
| BioChemical Class |
Immunoglobulin
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | IMGN901 | Drug Info | Phase 2 | Solid tumour/cancer | [2] | |
| 2 | FGLL | Drug Info | Phase 1 | Alzheimer disease | [3] | |
| Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
| 1 | ERIC-1 | Drug Info | Terminated | Solid tumour/cancer | [4] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | IMGN901 | Drug Info | [1], [5] | |||
| 2 | FGLL | Drug Info | [3] | |||
| Antagonist | [+] 1 Antagonist drugs | + | ||||
| 1 | ERIC-1 | Drug Info | [6] | |||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 2 KEGG Pathways | + | ||||
| 1 | Cell adhesion molecules (CAMs) | |||||
| 2 | Prion diseases | |||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66. | |||||
| REF 2 | ClinicalTrials.gov (NCT02420873) A Study of Lorvotuzumab Mertansine. U.S. National Institutes of Health. | |||||
| REF 3 | An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res. 2013 Jun;38(6):1208-18. | |||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004519) | |||||
| REF 5 | Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Nov;60(11):1860-7. | |||||
| REF 6 | Monoclonal antibody UJ13A recognizes the neural cell adhesion molecule (NCAM). Int J Cancer. 1989 Dec 15;44(6):1062-8. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.